

10/516421

Atty. Docket No.: 62526US(50221)

DT09 Rec'd PCT/PTO 29 NOV 2004

IN THE UNITED STATES PATENT DESIGNATED OFFICE (DO/US)

(National Phase of International Appln.: PCT/GB03/02369

Publication No. WO 03/102237 A1)

In re the
application of: **CLERICI, Mario *et al.***

International Application No.: **PCT/GB03/02369**

International Filing Date: **30 May 2003**

U.S. Serial No.: **Not yet assigned**

Filed: **Herewith**

For: ***TREATMENT WITH CYTOKINES FOR
ALZHEIMER'S DISEASE***

Attorney Docket No.: **62526US(50221)**


**Mailstop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

"Express Mail" mailing label number EV 517929867 US Date of Deposit November 29, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mailstop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Peter C. Lauro, Esq.

Please Print Name of Person Signing



Signature

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration.

Because publications A1-A8 have previously been transmitted by the International Bureau, along with the Search Report, to all the Designated Offices in the corresponding International patent application PCT/GB03/02369, Applicants do not enclose copies of these publications herewith.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(1), no additional costs are believed to be due in connection with the filing of this disclosure. However, please charge any fee necessary for consideration of this statement to our Deposit Order Account No. 04-1105.

Respectfully submitted,
EDWARDS & ANGELL, LLP



Peter C. Lauro, Esq.
Registration No. 32,360
Attorney for Applicants

P.O. Box 55874
Boston, MA 02205
(617) 517-5509

Date: November 29, 2004

Enclosure

Customer No. 21874

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80 LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO 62526US(50221) APPLICANT Mario Clerici. et al. FILING DATE Herewith	SERIAL NO. Not Yet Assigned 10/516421 GROUP
---	---	--	--

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	WO 95/33992 A	12/14/95	US			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

		A2	LIO D ET AL: "Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease." GENES AND IMMUNITY, vol.4, no.3, April 2003 (2003-04). Pages 234-238, XP001155652, ISSN: 1466-4879 (ISSN print), page 236: tables 1,2
		A3	REMARQUE E J ET AL: "Patients with Alzheimer's disease display a pro-inflammatory phenotype" EXPERIMENTAL GERONTOLOGY, vol. 36, no.1, January 2001 (2001-01), pages 171-176, XP002257920, ISSN: 0531-5565, page 173-page 175; table 1
		A4	TURNER D M ET AL: "AN INVESTIGATION OF POLYMORPHISM IN THE INTERLEUKIN-10 GENE PROMOTER" EUROPEAN JOURNAL OF IMMUNOGENETICS, OXFORD, GB, vol. 24, no. 1, 1997, pages 1-8, XP000865679, ISSN: 0960-7420, page 6; figure 1
		A5	PAPASSOTIROPOULOS ANDREAS ET AL; "Genetics of interleukin 6: Implications for Alzheimer's disease" NEUROBIOLOGY OF AGING, vol. 22, no.6, November 2001 (2001-11), pages 863-871, XP002257921, ISSN: 0197-4580, page 867, left-hand column - page 868, left-hand column
		A6	MARTIN E R ET AL: "SNPING AWAY AT COMPLEX DISEASES: ANALYSIS OF SINGLE-NUCLEOTIDE POLYMORPHISMS AROUND APOE IN ALZHEIMER DISEASE" AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol 67, august 2000 (2000-08), pages 383-394, XP000995224, ISSN: 002-9297, page 384- page 385
		A7	DEPBOYLU CANDAN ET AL: "Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease." NEUROSCIENCE LETTERS, vol. 342, no. 1-2, 15 May 2003 (2003-05-15), pages 132-134, XP001155649, ISSN: 0304-3940 (ISSN print) the whole document
		A8	SZCZEPANIK A M ET AL: "IL-4, IL-10 AND IL-13 modulate ab(1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line" JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 113, no. 1, 2001, pages 49-62, XP002955731, ISSN: 0165-5728 the whole document
Examiner			Date Considered
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			